Discordant Phenotypes of Nephritis in Patients with X-linked Agammaglobulinemia.
Humans
Agammaglobulinemia
/ immunology
Genetic Diseases, X-Linked
/ immunology
Male
Phenotype
Adolescent
Child
Adult
Retrospective Studies
Child, Preschool
Young Adult
Agammaglobulinaemia Tyrosine Kinase
/ genetics
Nephritis, Interstitial
/ immunology
Kidney
/ pathology
B-Lymphocytes
/ immunology
Female
Glomerulonephritis
/ immunology
Nephritis
/ immunology
Chronic glomerulonephritis
Immunoglobulin replacement therapy
Leaky B cells
Tubulointerstitial nephritis
X-linked agammaglobulinemia
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
24
04
2024
accepted:
14
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
To define the clinical and histological characteristics of nephritis in patients with X-linked agammaglobulinemia (XLA) and their immunological profiles. The clinical, immunological, and histological findings of nine patients with XLA and nephritis were retrospectively analyzed. Based on kidney histological findings, patients with XLA and nephritis could be divided into two groups, viz., chronic glomerulonephritis (CGN) and tubulointerstitial nephritis (TIN). The two groups showed different immunological profiles. Patients in the CGN group exhibited an atypical immunological profile of XLA, with pathogenic leaky B cells producing immunoglobulins that may play a role in forming immune complexes and causing immune-mediated glomerulonephritis. In contrast, patients in the TIN group exhibited a typical immunological profile of XLA, suggesting that antibody-independent/other BTK-dependent mechanisms, or immunoglobulin replacement therapy (IgRT)-related immune/nonimmune-mediated nephrotoxicity causes TIN. Nephritis occurring in patients with XLA could have links between their renal pathology and immunological status. Careful observation is recommended to detect kidney pathology in patients with XLA on IgRT.
Identifiants
pubmed: 39052129
doi: 10.1007/s10875-024-01766-x
pii: 10.1007/s10875-024-01766-x
doi:
Substances chimiques
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Subventions
Organisme : MEXT/JSPS KAKENHI
ID : 22K07887
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.
doi: 10.1007/s10875-022-01289-3
pubmed: 35748970
pmcid: 9244088
Hernandez-Trujillo V, Zhou C, Scalchunes C, Ochs HD, Sullivan KE, Cunningham-Rundles C, et al. A Registry Study of 240 patients with X-Linked agammaglobulinemia living in the USA. J Clin Immunol. 2023;43(6):1468–77.
doi: 10.1007/s10875-023-01502-x
pubmed: 37219739
pmcid: 10354121
Shajari A, Zare Ahmadabadi A, Ashrafi MM, Mahdavi T, Mirzaee M, Mohkam M et al. Inborn errors of immunity with kidney and urinary tract disorders: a review. Int Urol Nephrol. 2024.
Conley ME, Rohrer J, Minegishi Y. X-Linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183–204.
doi: 10.1385/CRIAI:19:2:183
pubmed: 11107501
Schwaber J, Chen RH. Premature termination of variable gene rearrangement in B lymphocytes from X-linked agammaglobulinemia. J Clin Invest. 1988;81(6):2004–9.
doi: 10.1172/JCI113550
pubmed: 2838527
pmcid: 442655
Yoshino A, Honda M, Kanegane H, Obata K, Matsukura H, Sakazume S, et al. Membranoproliferative glomerulonephritis in a patient with X-linked agammaglobulinemia. Pediatr Nephrol. 2006;21(1):36–8.
doi: 10.1007/s00467-005-2029-z
pubmed: 16550363
Endo LM, Giannobile JV, Dobbs AK, Foote JB, Szymanska E, Warnock DG, et al. Membranous glomerulopathy in an adult patient with X-linked agammaglobulinemia receiving intravenous gammaglobulin. J Investig Allergol Clin Immunol. 2011;21(5):405–9.
pubmed: 21905506
pmcid: 3667600
Lim LM, Chang JM, Wang IF, Chang WC, Hwang DY, Chen HC. Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient. BMC Pediatr. 2013;13:150.
doi: 10.1186/1471-2431-13-150
pubmed: 24074005
pmcid: 3849551
Lavrador V, Correia F, Sampaio R, Candido C, Sameiro-Faria M, Marques L, et al. Membranoproliferative glomerulonephritis and x-linked agammaglobulinemia: an uncommon association. Case Rep Pediatr. 2014;2014:480947.
pubmed: 24716070
pmcid: 3971515
Sugimoto K, Nishi H, Miyazawa T, Wada N, Izu A, Enya T, et al. Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia. BMC Nephrol. 2014;15:109.
doi: 10.1186/1471-2369-15-109
pubmed: 25005715
pmcid: 4094640
Takeguchi M, Korematsu S, Miyahara H, Kuga S, Izumi T. IVIG-triggered tubulointerstitial nephritis in X-linked agammaglobulinemia. Pediatr Int. 2017;59(8):945–6.
doi: 10.1111/ped.13329
pubmed: 28707726
Kanegane H, Futatani T, Wang Y, Nomura K, Shinozaki K, Matsukura H, et al. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J Allergy Clin Immunol. 2001;108(6):1012–20.
doi: 10.1067/mai.2001.120133
pubmed: 11742281
Bucciol G, Moens L, Payne K, Wollants E, Mekahli D, Levtchenko E, et al. Chronic Aichi Virus Infection in a patient with X-Linked agammaglobulinemia. J Clin Immunol. 2018;38(7):748–52.
doi: 10.1007/s10875-018-0558-z
pubmed: 30311057
Gonzalo-Garijo MA, Sanchez-Vega S, Perez-Calderon R, Perez-Rangel I, Corrales-Vargas S, Fernandez de Mera JJ, et al. Renal amyloidosis in a patient with X-linked agammaglobulinemia (Bruton’s disease) and bronchiectasis. J Clin Immunol. 2014;34(1):119–22.
doi: 10.1007/s10875-013-9972-4
pubmed: 24292696
Caza TN, Hassen SI, Larsen CP. Renal manifestations of common variable immunodeficiency. Kidney360. 2020;1(6):491–500.
doi: 10.34067/KID.0000432020
pubmed: 35368588
pmcid: 8809320
Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr. 2002;141(4):566–71.
doi: 10.1067/mpd.2002.127711
pubmed: 12378199
Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol. 2006;118(2–3):201–8.
doi: 10.1016/j.clim.2005.11.002
pubmed: 16377251
Hunter HL, McKenna KE, Edgar JD. Eczema and X-linked agammaglobulinaemia. Clin Exp Dermatol. 2008;33(2):148–50.
doi: 10.1111/j.1365-2230.2007.02582.x
pubmed: 18076688
Ochs HD, Notarangelo LD. X-linked immunodeficiencies. Curr Allergy Asthma Rep. 2004;4(5):339–48.
doi: 10.1007/s11882-004-0082-5
pubmed: 15283872
Verbruggen G, De Backer S, Deforce D, Demetter P, Cuvelier C, Veys E, et al. X linked agammaglobulinaemia and rheumatoid arthritis. Ann Rheum Dis. 2005;64(7):1075–8.
doi: 10.1136/ard.2004.030049
pubmed: 15564308
Nonoyama S, Tsukada S, Yamadori T, Miyawaki T, Jin YZ, Watanabe C, et al. Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia. J Immunol. 1998;161(8):3925–9.
doi: 10.4049/jimmunol.161.8.3925
pubmed: 9780159
Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.
doi: 10.1006/clim.2002.5241
pubmed: 12217331
Goyal R, Bulua AC, Nikolov NP, Schwartzberg PL, Siegel RM. Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders. Curr Opin Rheumatol. 2009;21(1):78–84.
doi: 10.1097/BOR.0b013e32831cb939
pubmed: 19077721
pmcid: 2760066
Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J Clin Immunol. 2013;33(Suppl 2):S95–8.
doi: 10.1007/s10875-012-9853-2
pubmed: 23264027
Doyle SL, Jefferies CA, Feighery C, O’Neill LA. Signaling by toll-like receptors 8 and 9 requires Bruton’s tyrosine kinase. J Biol Chem. 2007;282(51):36953–60.
doi: 10.1074/jbc.M707682200
pubmed: 17932028
Lee KG, Xu S, Wong ET, Tergaonkar V, Lam KP. Bruton’s tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B cells. J Biol Chem. 2008;283(17):11189–98.
doi: 10.1074/jbc.M708516200
pubmed: 18276597
Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O’Neill LA. Bruton’s tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS ONE. 2013;8(8):e74103.
doi: 10.1371/journal.pone.0074103
pubmed: 23967355
pmcid: 3743783
Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956–61.
doi: 10.1038/ki.2010.89
pubmed: 20336051
Zhang T, Wang M, Zhang J, Feng X, Liu Z, Cheng Z. Association between tubulointerstitial CD8
Sementilli A, Franco M. Renal acute cellular rejection: correlation between the immunophenotype and cytokine expression of the inflammatory cells in acute glomerulitis, arterial intimitis, and tubulointerstitial nephritis. Transplant Proc. 2010;42(5):1671-6.
Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186(3):1849–60.
doi: 10.4049/jimmunol.1001983
pubmed: 21187439
Levy JB, Pusey CD. Nephrotoxicity of intravenous immunoglobulin. QJM. 2000;93(11):751–5.
doi: 10.1093/qjmed/93.11.751
pubmed: 11077032
Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176–94.
doi: 10.1016/j.amjms.2020.10.003
pubmed: 33309134
Schena FP, Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin Nephrol. 2018;38(5):435–42.
doi: 10.1016/j.semnephrol.2018.05.013
pubmed: 30177015